Abstract:Neisseria gonorrhoeae is a major public health concern because of the high incidence of gonorrhea and the increasingly limited options for antimicrobial therapy. Strains associated with the FC428 clone are a particular concern because they have shown global dissemination and they display high-level resistance against the currently recommended ceftriaxone therapy. ABSTRACT Alternative antimicrobial therapies are urgently required for the multidrug-resistant bacterial pathogen Neisseria gonorrhoeae, for which currently ceftriaxone is the only remaining recommended first-line therapy. Repurposing of drugs that are approved for other clinical applications offers an efficient approach for development of alternative antimicrobial therapies. Auranofin, cannabidivarin, and tolfenamic acid were recently identified to display antimicrobial activity against N. gonorrhoeae. Here, we investigated their activity against a collection of 575 multidrug-resistant clinical isolates. All three compounds displayed consistent antimicrobial activity against all isolates, including against strains associated with the high-level ceftriaxone-resistant FC428 clone, with both the mode and MIC90 for auranofin of 0.5 mg/L, while both the mode and MIC90 for cannabidivarin and tolfenamic acid were 8 mg/L. Correlations between MICs of ceftriaxone and auranofin, cannabidivarin or tolfenamic acid were low, indicating that development of cross-resistance is unlikely. Furthermore, antimicrobial synergy analysis between ceftriaxone and auranofin, cannabidivarin, or tolfenamic acid by determination of the fractional inhibitory concentration index (FICI) resulted in an interpretation of indifference. Finally, time-kill analyses showed that all three compounds are bactericidal against both the N. gonorrhoeae ATCC 49226 reference strain and an FC428-associated clinical isolate, with particularly cannabidivarin displaying rapid bactericidal activity. Overall, auranofin, cannabidivarin, and tolfenamic acid displayed consistent antimicrobial activity against multidrug-resistant N. gonorrhoeae, warranting further exploration of their suitability as alternative antimicrobials for treatment of gonococcal infections. IMPORTANCE Neisseria gonorrhoeae is a major public health concern because of the high incidence of gonorrhea and the increasingly limited options for antimicrobial therapy. Strains associated with the FC428 clone are a particular concern because they have shown global dissemination and they display high-level resistance against the currently recommended ceftriaxone therapy. Therefore, development of alternative antimicrobial therapies is urgently required to ensure treatment of gonorrhea remains available in the future. Repurposing of clinically approved drugs could be a rapid approach for the development of such alternative antimicrobials. In this study, we showed that repurposing of auranofin, cannabidivarin, and tolfenamic acid for antimicrobial therapy of gonorrhea deserves further clinical explorations because these compounds displayed consistent antimicrobial activity against a large collection of contemporary multidrug-resistant gonococcal isolates that included strains associated with the FC428 clone.

Affinity of β-Lactam Antibiotics for Neisseria gonorrhoeae Penicillin-Binding Protein 2 Having Wild, Cefixime-Reduced-Susceptible, and Cephalosporin (Ceftriaxone)-Resistant penA Alleles

Impact of the Gonococcal FC428 Pena Allele 60.001 on Ceftriaxone Resistance and Biological Fitness.

Bacitracin Enhances Ceftriaxone Susceptibility of the High-Level Ceftriaxone-Resistant Gonococcal FC428 Clone

Combined Mutations of the Pena with Ftsx Genes Contribute to Ceftriaxone Resistance in Neisseria Gonorrhoeae and Peptide Nucleic Acids Targeting These Genes Reverse Ceftriaxone Resistance.

High-level Ceftriaxone Resistance Due to Transfer of Pena Allele 60.001 into Endemic Gonococcal Lineages in Hangzhou, China.

Antibiotic Resistance and Treatment Options for Multidrug-Resistant Gonorrhea

Ureidopenicillins Are Potent Inhibitors of Penicillin-Binding Protein 2 from Multidrug-Resistant Neisseria gonorrhoeae H041

High percentage of the ceftriaxone-resistant<i>Neisseria gonorrhoeae</i>FC428 clone among isolates from a single hospital in Hangzhou, China

High Percentage Of The Ceftriaxone-Resistant Neisseria Gonorrhoeae Fc428 Clone Among Isolates From A Single Hospital In Hangzhou, China

Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid Against Multidrug-Resistant Neisseria Gonorrhoeae

Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China.

Evolution of Ceftriaxone Resistance of Penicillin-Binding Proteins 2 Revealed by Molecular Modeling

Recognition of the β-lactam carboxylate triggers acylation of Neisseria gonorrhoeae penicillin-binding protein 2

Molecular Features of Cephalosporins Important for Activity against Antimicrobial-Resistant Neisseria gonorrhoeae

Molecular Basis of Influence of A501X Mutations in Penicillin-Binding Protein 2 of Neisseria gonorrhoeae Strain 35/02 on Ceftriaxone Resistance

Emergence of Meropenem Resistance Among Cefotaxime Non-susceptible Streptococcus pneumoniae: Evidence and Challenges

Identification of High-Level Ceftriaxone-Resistant Neisseria Gonorrhoeae Isolates with Diverse Pena Alleles in Zhejiang, China.

Recent Evolution of Susceptibility to Beta-Lactams in Neisseria meningitidis

penA profile of Neisseria gonorrhoeae in Guangdong, China: novel penA alleles are related to decreased susceptibility to ceftriaxone or cefixime

Predominant Porb1a and Porb1b Genotypes and Correlation of Gene Mutations with Drug Resistance in Neisseria Gonorrhoeae Isolates in Eastern China

Emergence and evolution of mosaic penA-60 and penA-237 alleles in a Neisseria gonorrhoeae core genogroup that was historically susceptible to extended spectrum cephalosporins